Compare 3M Company (MMM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? 3M Company trades at $164.93 (market cap $83.94B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: 3M Company is far larger — about 86.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and 3M Company pays a 1.92% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MMM | MRVI | |
|---|---|---|
Market Cap | $83.94B | $972.90M |
Volume | 2,547,210 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $183.79 | $9.00 |
52-Week Low | $141.10 | $2.83 |
Typical Hold Time | 169 Days | 0 Days |
Enterprise Value | $93.17B | $1.08B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $164.46, up 2.22% with strong recent earnings beats and a bullish analyst consensus price target of $191. The stock shows bearish technical signals but maintains solid fundamentals with 11.9% net margins and 82.77% ROE. Recent Q2 2026 results confirmed operational improvements with 5.4% organic growth and raised guidance, though technical indicators suggest near-term pressure.
The outlook remains positive with manageable litigation risks and strategic focus on high-growth areas like data centers. Key risks include consumer segment weakness and debt levels. Wall Street sentiment is balanced with 48% buy ratings, supporting potential upside from current levels despite technical bearishness.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
